% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Floerchinger:267536,
      author       = {A. Floerchinger$^*$ and J. E. Klein$^*$ and M. S. C.
                      Finkbeiner and T. Schäfer$^*$ and G. Fuchs$^*$ and J.
                      Doerner and H. Zirngibl and M. Ackermann and H. M. Kvasnicka
                      and K. A. Chester and D. Jäger and C. R. Ball$^*$ and G.
                      Ungerechts$^*$ and C. Engeland$^*$},
      title        = {{A} vector-encoded bispecific killer engager to harness
                      virus-activated {NK} cells as anti-tumor effectors.},
      journal      = {Cell death $\&$ disease},
      volume       = {14},
      number       = {2},
      issn         = {2041-4889},
      address      = {London [u.a.]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2023-00314},
      pages        = {104},
      year         = {2023},
      note         = {#EA:F230#LA:F230#},
      abstract     = {Treatment with oncolytic measles vaccines (MV) elicits
                      activation of immune cells, including natural killer (NK)
                      cells. However, we found that MV-activated NK cells show
                      only modest direct cytotoxic activity against tumor cells.
                      To specifically direct NK cells towards tumor cells, we
                      developed oncolytic measles vaccines encoding bispecific
                      killer engagers (MV-BiKE) targeting CD16A on NK cells and
                      carcinoembryonic antigen (CEA) as a model tumor antigen.
                      MV-BiKE are only slightly attenuated compared to parental MV
                      and mediate secretion of functional BiKE from infected tumor
                      cells. We tested MV-BiKE activity in cocultures of
                      colorectal or pancreatic cancer cells with primary human NK
                      cells. MV-BiKE mediate expression of effector cytokines,
                      degranulation and specific anti-tumor cytotoxicity by NK
                      cells. Experiments with patient-derived pancreatic cancer
                      cultures indicate that efficacy of MV-BiKE may vary between
                      individual tumors with differential virus permissiveness.
                      Remarkably, we confirmed MV-BiKE activity in primaryhuman
                      colorectal carcinoma specimens with autochthonous tumor and
                      NK cells.This study provides proof-of-concept for MV-BiKE as
                      a novel immunovirotherapy to harness virus-activated NK
                      cells as anti-tumor effectors.},
      cin          = {F230 / DD01},
      ddc          = {570},
      cid          = {I:(DE-He78)F230-20160331 / I:(DE-He78)DD01-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36765035},
      doi          = {10.1038/s41419-023-05624-3},
      url          = {https://inrepo02.dkfz.de/record/267536},
}